Please enable JavaScript.
Coggle requires JavaScript to display documents.
RSV Vaccines, Beyfortus, Abrysvo, News Event - Coggle Diagram
RSV Vaccines
AREXVY
This vaccine is approved and administered to individuals 60 or older (FDA, 2023)
Approved as a RSV vaccine on May 3, 2023. (FDA, 2023)
Recombinant protein vaccine that helps ones immune system build antibodies against RSV (CDC, 2024)
Side effects: swelling where a shot is given, nausea, diarrhea, muscle or joint pain, fever, and headaches; only reported to be mild
Patients should get the vaccine around fall time in order to ensure vaccine works accurately and according to RSV 'season' (CDC, 2023)
Arexvy is a "single intramuscular injection" (FDA, 2023)
News Event
RSV headlines as the emerging respiratory illness behind COVID-19 in recent years following the 2020 pandemic (CDC, 2024)
Beyfortus
-
It's main demographic is for kids up to 24 months (FDA, 2023)
Long acting vaccine (CDC, 2024)
It was introduced in 2023 (FDA, 2023)
Symptoms include: Pain, redness, swelling, and a rash. In rare and unlikely occassions, a severe allergic reaction or death. (CDC, 2023)
It is administered at the early life, in the up to 24 months, or all infants younger than 8 months. (CDC, 2023)
Abrysvo
-
This vaccine is administered to pregnant women, which helps the baby in-utero. (CDC,2023)
When Abrysvo begins working it strengthens the immune system. It makes it so when RSV antigens are detected the immune system will already be ready to fight against it. (CDC,2023)
It was released publicly 08/21/2023 (FDA,2023)
Some side effects include: pain at the injection site(arm), headache, muscle pain and nausea. Preterm birth, allergic reaction, and preeclampsia are rare but possible.(CDC, 2023)
Abrevsy is administered to women around 32-36 weeks (CDC, 2023)
News Event
In recent years, various sources such as the CDC and FDA have reported on three different vaccines meant to treat RSV in multiple age groups (CDC, 2024)
The promotion and continued research of these three prominent vaccines has helped to reduce the negative impacts of RSV in recent years. For example, Abrysvo reduces RSV hospitalizations in babies by 57% in the first 6 months after birth (CDC, 2023)